<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Yale J Biol Med</journal-id><journal-title>The Yale Journal of Biology and Medicine</journal-title><issn pub-type="ppub">0044-0086</issn><issn pub-type="epub">1551-4056</issn><publisher><publisher-name>Yale Journal of Biology and Medicine</publisher-name></publisher></journal-meta><article-meta><article-categories><subj-group subj-group-type="heading"><subject>Cancer Mechanisms</subject></subj-group><series-title>Cancer Issue</series-title></article-categories><title-group><article-title>Multiple Endocrine Neoplasia Type 1 (MEN1) as a Cancer Predisposition Syndrome: Clues into the Mechanisms of MEN1-related Carcinogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Busygina</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Bale</surname><given-names>Allen E.</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><aff id="A1"><label>a</label>Department of Biophysics and Biochemistry, Yale University School of Medicine, New Haven Connecticut</aff><aff id="A2"><label>b</label>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label>To whom all correspondence should be addressed: Valeria Busygina, Ph.D., Department of Biophysics and Biochemistry, Yale University School of Medicine, 333 Cedar Street, SHM C-130, New Haven, CT 06520. Tel: 203-785-4569; E-mail: <email>valeriya. busygina@yale.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><month>10</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2006</year></pub-date><volume>79</volume><issue>3-4</issue><fpage>105</fpage><lpage>114</lpage><permissions><copyright-statement>Copyright &#x000a9;2006, Yale Journal of Biology and Medicine</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Yale Journal of Biology and Medicine</copyright-holder><license license-type="open-access"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way.</p></license></permissions></article-meta></front><body><p>Cancer is a major public health problem in the United States and around the world with millions of new cases diagnosed each year. While most of the cancers occur sporadically, a number of familial cancer predisposition syndromes have been identified in recent years. Cancer susceptibility syndromes are responsible for an estimated 5 to 10 percent of all cancer cases. Genes responsible for hereditary cancers are often also mutated in sporadic cancers. Studies of cellular functions of cancer susceptibility genes have made an invaluable contribution to our understanding of tumorigenesis.</p><p>Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer predisposition syndrome, the gene for which encodes a nuclear protein: menin. The biochemical function of this protein is largely unknown, but several studies have shown a role in transcriptional modulation through interaction with histone deacetylases and histone methyltransferases. Tumors in MEN1 arise through a two-hit mechanism, suggesting that menin either negatively regulates cell growth or participates in maintenance of genomic integrity.</p><p>In this work, we provide a general overview of the hereditary cancer syndromes with both dominant and recessive mode of inheritance. We then discuss recent advances in understanding the biological role of <italic>MEN1</italic> gene and the mechanisms by which inactivation of MEN1 may lead to neoplastic transformation.</p><sec sec-type="discussion" id="s2"><title>Hereditary cancer predisposition syndromes</title><p>Despite the complexity of cancer as a disease, there are some common features shared by all cancer cells that distinguish them from their normal counterparts. They are immortal and have a high proliferative potential. They no longer require external growth signals to activate the proliferation program and are insensitive to growth inhibitory signals. They have developed mechanisms for evading senescence and programmed cell death, or apoptosis. In order to ensure tumor growth, the cells of solid tumors must promote the formation of new blood vessels for oxygen and nutrient supply. And, finally, malignant cells fail to exhibit normal cell-cell interactions, which results in their ability to invade and to metastasize and grow in an abnormal cellular environment [<xref ref-type="bibr" rid="R1">1</xref>]. The acquisition of these qualities is not a single event but rather the result of an accumulation of multiple genetic alterations leading to escape from normal control of growth regulation and differentiation [<xref ref-type="bibr" rid="R2">2</xref>].</p><p>Genes with very diverse cellular functions have been implicated in carcinogenesis. This includes genes involved in intracellular signaling cascades, cell cycle control, cell differentiation, apoptosis, protein synthesis and degradation, organization of cytoskeleton, cell migration, cell-cell interaction, regulation of transcription, chromatin remodeling, and DNA damage sensing and repair [<xref ref-type="bibr" rid="R3">3</xref>-<xref ref-type="bibr" rid="R5">5</xref>]. Understanding how the disruption of these cellular processes leads to tumor formation is the key to rational development of effective cancer therapies.</p><p>Because the development of cancer is a multi-step process, it may take years between the occurrence of the first genetic lesion and the actual formation of malignant neoplasm. Thus, the incidence of cancer increases with age. In rare cases, however, individuals inherit a mutant allele of a cancer predisposition gene, which increases the mutation rate and promotes the development of cancer. Thus, individuals with cancer predisposition syndromes have both a greater risk of developing cancer and an average earlier age of onset compared to the general population.</p><p>In 1971, Knudson proposed his famous &#x0201c;two-hit&#x0201d; hypothesis [<xref ref-type="bibr" rid="R6">6</xref>]. By observing patients with familial and sporadic retinoblastoma, he suggested that individuals with familial cases inherited the first genetic lesion, or &#x0201c;hit,&#x0201d; and that they only needed to acquire one more hit to develop cancer. These patients developed retinoblastoma at an earlier age than individuals with sporadic tumors who needed to acquire two somatic hits in the same cell. This hypothesis was confirmed with the discovery of the retinoblastoma (RB1) gene in 1986 [<xref ref-type="bibr" rid="R7">7</xref>]. Indeed, individuals with familial retinoblastoma inherited a germline mutation in one allele of the RB1 gene with the remaining wild type allele being lost in tumors, often through a process involving large deletions with loss of heterozygosity (LOH) for surrounding polymorphic loci [<xref ref-type="bibr" rid="R7">7</xref>].</p><p>Since the discovery of RB1, multiple tumor-predisposition genes have been identified by the study of familial cancer syndromes. It is estimated that 5 to 10 percent of all cancers develop in individuals who have inherited a mutation conferring cancer susceptibility [<xref ref-type="bibr" rid="R8">8</xref>]. Analysis of the genes responsible for hereditary cancer predisposition and the pathways in which they act has been critically important in providing insight into cancer formation, because the same genes that are affected in cancer-predisposition syndromes are often responsible for the majority of somatic cancer cases as well. For example, germline mutations in the APC gene account for less than one percent of all colorectal cancers, but APC is also inactivated in nearly all sporadic colon cancers [<xref ref-type="bibr" rid="R2">2</xref>].</p><p>More than 50 cancer predisposition syndromes have been identified to date [<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>] with both dominant and recessive modes of inheritance (Table 1). Activating mutations in oncogenes occur only in a few cases, such as RET in multiple endocrine neoplasia type 2 (MEN2) [<xref ref-type="bibr" rid="R10">10</xref>] and MET in familial papillary renal carcinoma [<xref ref-type="bibr" rid="R11">11</xref>]. Activated oncogenes function dominantly in the cell, and mutation of the second allele is not required. Most of the dominantly inherited cancer syndromes, however, have an inactivating mutation in a tumor suppressor, and disease formation follows the two-hit rule. The first hit is a germline mutation that exists in every cell of the body. Somatic inactivation of the second allele of the same locus in certain tissues may initiate neoplastic transformation. Thus, cancer predisposition syndromes often have dominant mode of inheritance at the level of the organism, but at the cellular level they are recessive because inactivation of both copies of the gene is required for cancer formation.</p><p>Genes whose inactivation leads to tumorigenesis are divided into two distinct groups: gatekeepers and caretakers. Gatekeepers are usually &#x0201c;classical&#x0201d; tumor suppressors that directly regulate cell growth, differentiation, and death in certain tissues. Dysregulation of a gatekeeper is necessary to initiate neoplastic transformation. Examples of gatekeepers include APC for colon epithelia, RB1 for retinal epithelia, NF1 for Schwann cells, and VHL for kidney cells [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R12">12</xref>]. Inactivation of both homologs of these genes is found both in hereditary forms of cancer and in the majority of sporadic cancers of the same type. In contrast to gatekeepers, caretaker genes do not directly regulate cell growth. Caretaker genes are involved in DNA repair and maintenance of genomic integrity. Inactivation of a caretaker does not directly promote tumor formation but facilitates the development of mutations in gatekeeper genes and other cancer-related genes. Caretakers, like gatekeepers, may be tissue-specific, but mutation in a caretaker is neither necessary nor sufficient for the development of cancer. Mutations in some caretaker genes cause human cancer by the two-hit mechanism. For example, patients with familial breast cancer syndromes inherit one mutant copy of BRCA1 or 2, and LOH for the second allele is found in tumors of breast and ovary [<xref ref-type="bibr" rid="R13">13</xref>-<xref ref-type="bibr" rid="R16">16</xref>]. Similarly, in hereditary non-polyposis colorectal cancer (HNPCC), one mutant copy of mismatch repair genes such as MLH1, MSH2, or MSH6 is inherited, and the wild type allele is lost in tumors of the colon [<xref ref-type="bibr" rid="R17">17</xref>]. However, unlike gatekeepers, mutations in caretakers are uncommon in sporadic tumors of the types seen in the hereditary disease [<xref ref-type="bibr" rid="R18">18</xref>].</p><p>A number of human cancer predisposition syndromes have a recessive mode of inheritance (Table 1). These syndromes are also called genetic instability syndromes, because one of the hallmarks of these diseases is chromosomal instability and hypersensitivity to various DNA damaging insults. The genes mutated in these diseases, such as ATM, Fanconi anemia complementation group, NBS1, Xeroderma pigmentosum-associated genes (XPA, XPC, etc.), BLM, and RECQL4, function in DNA damage sensing or repair [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>] and can be classified as caretakers by analogy with the BRCA and HNPCC genes.</p><p> Since the identification of the first cancer predisposition gene (RB1) in 1986, tremendous advances have been made in understanding the function of multiple genes implicated in both sporadic and hereditary cancers. However, the mechanism of action of many more recently identified genes is not well understood. Further studies are necessary to provide new insights into human neoplasia and improve the diagnosis and treatment of both sporadic and hereditary cancers.</p></sec><sec sec-type="discussion" id="s3"><title>Multiple endocrine neoplasia type 1 (MEN1)</title><p>Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer predisposition syndrome characterized by parathyroid, pancreatic islet, and pituitary tumors as well as other neoplasms such as gastrinomas, carcinoids, lipomas, angiofibromas, angiomyolipomas and thyroid tumors [<xref ref-type="bibr" rid="R19">19</xref>]. Clinical manifestations depend on the affected organ. Most MEN1-associated tumors are not metastatic but create clinical effects by overproduction of hormones such as insulin, glucagon, prolactin, parathyroid hormone, gastrin, growth hormone, or adrenocorticotropic hormone [<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref>]. The most common manifestation of the disease is parathyroid adenoma, with penetrance reaching almost 100 percent by the age of 50 [<xref ref-type="bibr" rid="R19">19</xref>]. Major causes of morbidity and mortality in MEN1 are gastrinomas and foregut carcinoids, which are often highly metastatic [<xref ref-type="bibr" rid="R19">19</xref>]. The estimated prevalence of MEN1 is one in 30,000 [<xref ref-type="bibr" rid="R21">21</xref>].</p><p><italic>MEN1</italic> was localized to chromosome 11q13 by linkage analysis, and the gene was later identified by positional cloning [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref>]. Tumors in MEN1 arise through the two-hit mechanism with germline mutation in one copy of the gene and somatic loss of the normal allele [<xref ref-type="bibr" rid="R22">22</xref>]. Germline mutations in <italic>MEN1</italic> are mainly nonsense or frameshift and are presumed to cause inactivation of the gene. The transcript of the <italic>MEN1</italic> gene contains an open reading frame predicted to encode 610 amino acid proteins. Analysis of the sequence of the protein menin showed two nuclear localization signals near the carboxyl terminus but has not provided any other clues to its function. Immunocytochemical studies of interphase somatic cells show that the protein is located in the nucleus [<xref ref-type="bibr" rid="R25">25</xref>]. Studies in human and mouse show that <italic>MEN1</italic> is expressed widely in adult and fetal tissues with high levels in the CNS, lung, liver, kidney, testis, and fetal thymus [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R26">26</xref>-<xref ref-type="bibr" rid="R28">28</xref>].</p><p>Among the earliest studies of menin function was a yeast two-hybrid analysis showing interaction between menin and JunD, a component of the AP-1 transcription factor [<xref ref-type="bibr" rid="R29">29</xref>]. Studies in mammalian tissue culture systems showed that the N-terminal half of menin could inhibit JunD-mediated transcription. Menin did not bind to other AP-1 components such as c-Jun, JunB, or four members of the Fos family. Further investigation of menin&#x02019;s involvement in JNK and other MAP kinase signaling cascades revealed that overexpression of <italic>MEN1</italic> in some cell lines inhibited ERK-mediated phosphorylation of JunD and Elk1 and JNK-dependent phosphorylation of JunD and c-Jun [<xref ref-type="bibr" rid="R30">30</xref>]. In addition, overexpression of menin in CHO-IR cells suppressed insulin-induced activation of AP-1 and transcriptional induction of c-Fos [<xref ref-type="bibr" rid="R31">31</xref>]. Similarly, menin was shown to bind to and inhibit transcriptional activation by several members of the NF-&#x003ba;B family of transcription factors [<xref ref-type="bibr" rid="R32">32</xref>]. Binding of menin to SMAD3 appears to enhance transcriptional activation function, and loss of menin blocks TGF beta signaling [<xref ref-type="bibr" rid="R33">33</xref>]. The homeobox-containing protein Pem [<xref ref-type="bibr" rid="R34">34</xref>] has also been shown to bind menin in biochemical assays. These data suggest that menin may act as a transcriptional regulator. Our investigations of the <italic>Drosophila MEN1</italic> homolog showed <italic>in vivo</italic> interaction of <italic>MEN1</italic> with JNK signaling pathway components. We also found that when tethered to DNA, <italic>Drosophila</italic> menin acts as a transcriptional repressor. Menin does not have any recognizable DNA binding motifs, and data are conflicting as to whether menin can directly bind DNA and whether it binds in a sequence-specific manner [<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>].</p><p>Multiple lines of evidence exist to support menin&#x02019;s involvement in transcriptional control and chromatin modification. Human menin was found to bind and control the activity of multiple transcription factors. Menin interacts with mSin3a, a component of the Sin3/Rpd3 HDAC complex [<xref ref-type="bibr" rid="R37">37</xref>], and with a histone methyltransferase complex containing the trithorax family proteins MLL2 and Ash2L [<xref ref-type="bibr" rid="R38">38</xref>-<xref ref-type="bibr" rid="R41">41</xref>]. In addition, menin was found to bind to the promoter regions of several homeobox genes and to regulate their expression [<xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R39">39</xref>]. Genome-wide analysis of genomic binding sites showed menin&#x02019;s localization to the promoters of multiple genes [<xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. Recently, two other transcription targets of menin were identified. Cyclin-dependent kinase inhibitors p27<sup>kip1</sup> and p18<sup>Ink4c</sup> are downregulated in menin-deficient cells, which also exhibited increased proliferation [<xref ref-type="bibr" rid="R40">40</xref>]. Thus, menin may control cell proliferation through regulating transcription of genes involved in cell cycle control.</p><p>That tumors in MEN1 arise through two-hit mechanism suggests that menin may act in the regulation of cell growth or in the maintenance of genomic integrity, as discussed above. Several lines of evidence suggest that menin might participate in DNA damage sensing or repair. Peripheral blood lymphocytes from MEN1 patients have an elevated frequency of chromosomal abnormalities after exposure to the cross-linking agent diepoxybutane (DEB) [<xref ref-type="bibr" rid="R44">44</xref>]. Menin-deficient mouse embryonic fibroblasts (MEFs) are hypersensitive to DEB [<xref ref-type="bibr" rid="R45">45</xref>]. Menin interacts with FANCD2, a gene that underlies the genetic instability syndrome Fanconi anemia. Moreover, this interaction is strengthened after the exposure of cells to &#x003b3;-irradiation [<xref ref-type="bibr" rid="R45">45</xref>]. In addition, menin was shown to interact with replication protein A (RPA) [<xref ref-type="bibr" rid="R46">46</xref>], a protein that binds single strand DNA and is important for several DNA repair pathways [<xref ref-type="bibr" rid="R47">47</xref>]. Studies from our laboratory show a role for the <italic>Drosophila</italic> homolog of <italic>MEN1</italic> in maintenance of genomic integrity. We found that inactivation of <italic>Men1</italic> in <italic>Drosophila</italic> results in flies that are sensitive to certain types of DNA damage, in particular to ionizing radiation and DNA cross-linking agents. In addition, <italic>Men1</italic>-deficient flies have an elevated mutation rate both at baseline and after treatment with ionizing radiation and nitrogen mustard (a cross-linking agent) [<xref ref-type="bibr" rid="R48">48</xref>]. Menin-deficient tissues from both <italic>Drosophila</italic> and mammals fail to undergo S-phase arrest in response to DNA damage by ionizing radiation [<xref ref-type="bibr" rid="R49">49</xref>]. These data suggest that tumor pathogenesis in the human disease may relate to genomic instability.</p><p> Studies also support a direct role for <italic>MEN1</italic> in the control of cell growth and differentiation. Overexpression of menin represses the proliferation and tumorigenesis of Ras-transformed NIH3T3 cells and insulinoma cells [<xref ref-type="bibr" rid="R50">50</xref>]. Data are conflicting as to whether menin-deficient mouse cells have increased proliferative capacity. One study found no cell-autonomous proliferative defects in <italic>Men1<sup>-/-</sup></italic> embryonic stem (ES) cells or embryonic fibroblasts (MEF) [<xref ref-type="bibr" rid="R51">51</xref>]. However, another study showed that <italic>Men1<sup>-/-</sup></italic> MEFs have increased proliferative capacity, and reintroduction of wild type menin suppresses their growth, possibly through an interaction with activator of S-phase kinase (ASK), a component of the Cdc7/ASK kinase complex [<xref ref-type="bibr" rid="R52">52</xref>]. Some phenotypes seen in mouse models of MEN1 suggest a direct role in growth control. For example, tissue-specific gene inactivation in pancreatic islet cells of the mouse leads to widespread hyperplasia, consistent with a similar role for the gene postnatally [<xref ref-type="bibr" rid="R53">53</xref>].</p><p>A mouse model with targeted disruption of the <italic>Men1</italic> gene showed that menin has an essential role in development [<xref ref-type="bibr" rid="R54">54</xref>]. The phenotype of heterozygotes was very similar to the human MEN1 phenotype with tumors of the parathyroid, pituitary, pancreatic islets, thyroid, and adrenal cortex. Homozygous mice died in utero. They appeared normal at E9.5 but by E11.5-12.5 were developmentally delayed and smaller than normal littermates. Virtually all fetuses were resorbed by E14.5. Morphological defects included an open neural tube, hypoplastic myocardium, and an extremely malformed liver with abnormal organization of the epithelial and hematopoietic compartments and increased apoptosis [<xref ref-type="bibr" rid="R51">51</xref>]. Conditional knockout of <italic>Men1</italic> in mouse pituitary and pancreatic islets showed that both these organs were able to develop normally even if <italic>Men1</italic> was deleted in early embryogenesis. Pancreatic islets developed &#x003b2;-cell hyperplasia and later, in six- to 12-month-old mice, pancreatic islet adenomas. Insulinomas and prolactinomas developed in some animals starting at nine months. The late tumorigenesis in these mice suggests that additional somatic events are necessary to promote cancer formation [<xref ref-type="bibr" rid="R53">53</xref>,<xref ref-type="bibr" rid="R55">55</xref>].</p><p>Two studies suggested a function of menin related to telomeres. Investigations in our laboratory [<xref ref-type="bibr" rid="R56">56</xref>] showed that menin localizes to telomeres during meiotic prophase in mouse spermatocytes. Menin foci were seen only at this location and not in other regions of meiotic cells. The foci were apparent as soon as axial elements began to form, and signals increased in intensity throughout prophase. However, menin did not co-localize with telomeric proteins, such as TRF2, in somatic cells at any stage of the cell cycle. Furthermore, telomeres of MEN1-related tumors were no different in length than telomeres of histologically similar sporadic tumors arising without <italic>MEN1</italic> mutations. Overexpression of menin did not influence telomerase activity as assessed by TRAP assays. Another study, which systematically examined the effects of tumor suppressor genes on telomere maintenance, suggested that loss of menin function might stimulate telomerase (hTERT) expression [<xref ref-type="bibr" rid="R57">57</xref>] and that menin might be involved in tumorigenesis through this mechanism.</p><p>Menin has also been found to associate with several cytoskeleton components. Menin&#x02019;s interaction with the intermediate filament proteins GFAP and vimentin was suggested to control its nuclear import [<xref ref-type="bibr" rid="R58">58</xref>]. Another cytoskeletal interactor of menin is nonmuscle myosin II-A heavy chain protein, which was found to co-localize with menin at the cleavage furrow during cytokinesis [<xref ref-type="bibr" rid="R59">59</xref>].</p></sec><sec sec-type="conclusions" id="s4"><title>Conclusions and outlook</title><p>In the 10 years since the <italic>MEN1</italic> gene was first cloned, a wealth of information concerning its possible function in tumorigenesis has been obtained. The accumulated genetic and biochemical data show that menin has multiple binding partners in a cell. By virtue of interacting with several transcription factors, menin is proposed to be involved in signaling pathways such as JNK, MAPK, TGF beta, and NF-&#x003ba;B; all of which have a well-documented role in cancer formation [<xref ref-type="bibr" rid="R60">60</xref>-<xref ref-type="bibr" rid="R63">63</xref>]. At the same time, through its role in chromatin modification, menin has been shown to affect the expression of c-Fos, hTERT, p27<sup>kip1</sup>, and p18<sup>Ink4c</sup>, which are also linked to neoplastic transformation [<xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R60">60</xref>,<xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R65">65</xref>]. On the cellular level, menin has been shown to regulate cell cycle progression and genomic integrity, both of which are often associated with a cancer phenotype.</p><p>The multiple functions of <italic>MEN1</italic> are not altogether unconnected. As a regulator of transcription, menin could control the expression of multiple factors involved in cell cycle regulation and the DNA damage response (see the examples above). The transcription regulation is likely achieved through menin&#x02019;s function in chromatin modification. At the same time, there is a wealth of evidence connecting the modification of chromatin with the maintenance of genome integrity [<xref ref-type="bibr" rid="R66">66</xref>]. Finally, the possibilities of MEN1&#x02019;s involvement in cell cycle regulation and genome maintenance are not mutually exclusive. MEN1 was shown to regulate proper S-phase arrest in response to exogenous DNA damage [<xref ref-type="bibr" rid="R49">49</xref>]. Similar regulation is necessary in the cell as endogenous DNA damage occurs every cell cycle during DNA replication [<xref ref-type="bibr" rid="R67">67</xref>].</p><p>Taken together, the accumulated knowledge of <italic>MEN1&#x02019;s</italic> potential functions and cellular partners suggests several possible mechanisms of its involvement in cancer formation. The key question is which of these functions or interactions play critical role in cancer development. One possible way to address this challenging problem is systematic investigation of tumors obtained from Men1 heterozygous mice as well as from MEN1 patients. One such study generated p18(-/-)Men1(+/-) and p27(-/-)Men1(+/-) mice and found that p18 functionally collaborates with MEN1 in suppressing lung and neuroendocrine tumors [<xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R65">65</xref>]. Another important question is whether menin aids in the maintenance of genome integrity by regulating the cell cycle or by serving as a structural component of DNA repair machinery. To this end, analysis of mutational spectra could point to a DNA repair step(s) most deficient in cells lacking <italic>MEN1</italic>. Careful examination of interactions between menin and known DNA repair proteins is also necessary. Addressing these issues is of key importance for the understanding of <italic>MEN1</italic>-related carcinogenesis and for the development of effective therapeutic approaches.</p></sec></body><back><ref-list><ref id="R1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><year>2000</year><volume>100</volume><issue>1</issue><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10647931</pub-id></citation></ref><ref id="R2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Lessons from hereditary colorectal cancer</article-title><source>Cell</source><year>1996</year><volume>87</volume><issue>2</issue><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">8861899</pub-id></citation></ref><ref id="R3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group><source>Oncogenes</source><year>1995</year><edition>2nd ed</edition><publisher-loc>Sudbury, Massachusetts</publisher-loc><publisher-name>Jones and Bartlett Publishers</publisher-name></citation></ref><ref id="R4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Principles of tumor suppression</article-title><source>Cell</source><year>2004</year><volume>116</volume><issue>2</issue><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">14744434</pub-id></citation></ref><ref id="R5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cress</surname><given-names>WD</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><article-title>Histone deacetylases, transcriptional control, and cancer</article-title><source>J Cell Physiol</source><year>2000</year><volume>184</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10825229</pub-id></citation></ref><ref id="R6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>AG Jr.</given-names></name></person-group><article-title>Mutation and cancer: statistical study of retinoblastoma</article-title><source>Proc Natl Acad Sci USA</source><year>1971</year><volume>68</volume><issue>4</issue><fpage>820</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">5279523</pub-id></citation></ref><ref id="R7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friend</surname><given-names>SH</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Rogelj</surname><given-names>S</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><name><surname>Rapaport</surname><given-names>JM</given-names></name><name><surname>Albert</surname><given-names>DM</given-names></name><name><surname>Dryja</surname><given-names>TP</given-names></name></person-group><article-title>A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma</article-title><source>Nature</source><year>1986</year><volume>323</volume><issue>6089</issue><fpage>643</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">2877398</pub-id></citation></ref><ref id="R8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name></person-group><article-title>Hereditary cancer predisposition syndromes</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>2</issue><fpage>276</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">15637391</pub-id></citation></ref><ref id="R9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>ER</given-names></name></person-group><article-title>Human cancer syndromes: clues to the origin and nature of cancer</article-title><source>Science</source><year>1997</year><volume>278</volume><issue>5340</issue><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">9353177</pub-id></citation></ref><ref id="R10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>LM</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Clayton</surname><given-names>D</given-names></name><name><surname>Kwok</surname><given-names>JB</given-names></name><name><surname>Gardner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC</article-title><source>Nat Genet</source><year>1994</year><volume>6</volume><issue>1</issue><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">7907913</pub-id></citation></ref><ref id="R11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Duh</surname><given-names>FM</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Kishida</surname><given-names>T</given-names></name><name><surname>Glenn</surname><given-names>G</given-names></name><name><surname>Choyke</surname><given-names>P</given-names></name><etal/></person-group><article-title>Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</article-title><source>Nat Genet</source><year>1997</year><volume>16</volume><issue>1</issue><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9140397</pub-id></citation></ref><ref id="R12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>AG</given-names></name></person-group><article-title>Antioncogenes and human cancer</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><issue>23</issue><fpage>10914</fpage><lpage>10921</lpage><pub-id pub-id-type="pmid">7902574</pub-id></citation></ref><ref id="R13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cannon-Albright</surname><given-names>LA</given-names></name><name><surname>Skolnick</surname><given-names>MH</given-names></name></person-group><article-title>The genetics of familial breast cancer</article-title><source>Semin Oncol</source><year>1996</year><volume>23</volume><issue>1</issue><supplement>2</supplement><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8614840</pub-id></citation></ref><ref id="R14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>CM</given-names></name><name><surname>Cochran</surname><given-names>C</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><etal/></person-group><article-title>BRCA2 mutations in primary breast and ovarian cancers</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><issue>2</issue><fpage>238</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">8640235</pub-id></citation></ref><ref id="R15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Kasumi</surname><given-names>F</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><article-title>Mutation analysis in the BRCA2 gene in primary breast cancers</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><issue>2</issue><fpage>245</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">8640237</pub-id></citation></ref><ref id="R16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>DH</given-names></name><name><surname>Bogden</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Baumgard</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><etal/></person-group><article-title>Low incidence of BRCA2 mutations in breast carcinoma and other cancers</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><issue>2</issue><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">8640236</pub-id></citation></ref><ref id="R17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Chan</surname><given-names>TL</given-names></name><name><surname>Ho</surname><given-names>JW</given-names></name><name><surname>Chan</surname><given-names>AS</given-names></name><name><surname>Chung</surname><given-names>LP</given-names></name><name><surname>Lam</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><issue>49</issue><fpage>7585</fpage><lpage>7592</lpage><pub-id pub-id-type="pmid">12386821</pub-id></citation></ref><ref id="R18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Cancer-susceptibility genes. Gatekeepers and caretakers</article-title><source>Nature</source><year>1997</year><volume>386</volume><issue>6627</issue><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">9126728</pub-id></citation></ref><ref id="R19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schussheim</surname><given-names>DH</given-names></name><name><surname>Skarulis</surname><given-names>MC</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Simonds</surname><given-names>WF</given-names></name><name><surname>Burns</surname><given-names>AL</given-names></name><name><surname>Spiegel</surname><given-names>AM</given-names></name><name><surname>Marx</surname><given-names>SJ</given-names></name></person-group><article-title>Multiple endocrine neoplasia type 1: new clinical and basic findings</article-title><source>Trends Endocrinol Metab</source><year>2001</year><volume>12</volume><issue>4</issue><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11295574</pub-id></citation></ref><ref id="R20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trump</surname><given-names>D</given-names></name><name><surname>Farren</surname><given-names>B</given-names></name><name><surname>Wooding</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>JT</given-names></name><name><surname>Besser</surname><given-names>GM</given-names></name><name><surname>Buchanan</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Clinical studies of multiple endocrine neoplasia type 1 (MEN1)</article-title><source>Qjm</source><year>1996</year><volume>89</volume><issue>9</issue><fpage>653</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">8917740</pub-id></citation></ref><ref id="R21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Lee Burns</surname><given-names>A</given-names></name><name><surname>Sukhodolets</surname><given-names>KE</given-names></name><name><surname>Kennedy</surname><given-names>PA</given-names></name><name><surname>Obungu</surname><given-names>VH</given-names></name><name><surname>Hickman</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Molecular pathology of the MEN1 gene</article-title><source>Ann NY Acad Sci</source><year>2004</year><volume>1014</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">15153434</pub-id></citation></ref><ref id="R22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>C</given-names></name><name><surname>Skogseid</surname><given-names>B</given-names></name><name><surname>Oberg</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name></person-group><article-title>Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma</article-title><source>Nature</source><year>1988</year><volume>332</volume><issue>6159</issue><fpage>85</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">2894610</pub-id></citation></ref><ref id="R23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Manickam</surname><given-names>P</given-names></name><name><surname>Olufemi</surname><given-names>SE</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Emmert-Buck</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Positional cloning of the gene for multiple endocrine neoplasia-type 1</article-title><source>Science</source><year>1997</year><volume>276</volume><issue>5311</issue><fpage>404</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9103196</pub-id></citation></ref><ref id="R24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemmens</surname><given-names>I</given-names></name><name><surname>Van de Ven</surname><given-names>WJ</given-names></name><name><surname>Kas</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>CX</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><name><surname>Wautot</surname><given-names>V</given-names></name><etal/></person-group><article-title>Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1</article-title><source>Hum Mol Genet</source><year>1997</year><volume>6</volume><issue>7</issue><fpage>1177</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">9215690</pub-id></citation></ref><ref id="R25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Goldsmith</surname><given-names>PK</given-names></name><name><surname>Burns</surname><given-names>AL</given-names></name><name><surname>Marx</surname><given-names>SJ</given-names></name><name><surname>Spiegel</surname><given-names>AM</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name></person-group><article-title>Menin, the product of the MEN1 gene, is a nuclear protein</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><issue>4</issue><fpage>1630</fpage><lpage>1634</lpage><pub-id pub-id-type="pmid">9465067</pub-id></citation></ref><ref id="R26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname><given-names>JH</given-names></name><name><surname>Rashbass</surname><given-names>P</given-names></name><name><surname>Harding</surname><given-names>B</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Pannett</surname><given-names>AA</given-names></name><name><surname>Thakker</surname><given-names>RV</given-names></name></person-group><article-title>Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1</article-title><source>J Bone Miner Res</source><year>1999</year><volume>14</volume><issue>1</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9893060</pub-id></citation></ref><ref id="R27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>KD</given-names></name><name><surname>Dunn</surname><given-names>KJ</given-names></name><name><surname>Manickam</surname><given-names>P</given-names></name><name><surname>Prasad</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene</article-title><source>Mamm Genome</source><year>1999</year><volume>10</volume><issue>6</issue><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">10341092</pub-id></citation></ref><ref id="R28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Parente</surname><given-names>F</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name><name><surname>Farnebo</surname><given-names>F</given-names></name><name><surname>Quincey</surname><given-names>D</given-names></name><name><surname>Silins</surname><given-names>G</given-names></name><etal/></person-group><article-title>Characterization of the mouse Men1 gene and its expression during development</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><issue>19</issue><fpage>2485</fpage><lpage>2493</lpage><pub-id pub-id-type="pmid">9824159</pub-id></citation></ref><ref id="R29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Heppner</surname><given-names>C</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Collins</surname><given-names>RM</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription</article-title><source>Cell</source><year>1999</year><volume>96</volume><issue>1</issue><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">9989505</pub-id></citation></ref><ref id="R30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>A</given-names></name><name><surname>Cuozzo</surname><given-names>C</given-names></name><name><surname>Esposito</surname><given-names>I</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name><name><surname>Bonofiglio</surname><given-names>D</given-names></name><name><surname>Vivacqua</surname><given-names>A</given-names></name><etal/></person-group><article-title>Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><issue>42</issue><fpage>6434</fpage><lpage>6445</lpage><pub-id pub-id-type="pmid">12226747</pub-id></citation></ref><ref id="R31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yumita</surname><given-names>W</given-names></name><name><surname>Ikeo</surname><given-names>Y</given-names></name><name><surname>Yamauchi</surname><given-names>K</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Hashizume</surname><given-names>K</given-names></name></person-group><article-title>Suppression of insulin-induced AP-1 transactivation by menin accompanies inhibition of c-Fos induction</article-title><source>Int J Cancer</source><year>2003</year><volume>103</volume><issue>6</issue><fpage>738</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">12516092</pub-id></citation></ref><ref id="R32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>C</given-names></name><name><surname>Bilimoria</surname><given-names>KY</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Kester</surname><given-names>M</given-names></name><name><surname>Whitty</surname><given-names>LJ</given-names></name><name><surname>Guru</surname><given-names>SC</given-names></name><etal/></person-group><article-title>The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><issue>36</issue><fpage>4917</fpage><lpage>4925</lpage><pub-id pub-id-type="pmid">11526476</pub-id></citation></ref><ref id="R33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaji</surname><given-names>H</given-names></name><name><surname>Canaff</surname><given-names>L</given-names></name><name><surname>Lebrun</surname><given-names>JJ</given-names></name><name><surname>Goltzman</surname><given-names>D</given-names></name><name><surname>Hendy</surname><given-names>GN</given-names></name></person-group><article-title>Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>7</issue><fpage>3837</fpage><lpage>3842</lpage><pub-id pub-id-type="pmid">11274402</pub-id></citation></ref><ref id="R34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemmens</surname><given-names>IH</given-names></name><name><surname>Forsberg</surname><given-names>L</given-names></name><name><surname>Pannett</surname><given-names>AA</given-names></name><name><surname>Meyen</surname><given-names>E</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name><name><surname>Turner</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Menin interacts directly with the homeobox-containing protein Pem</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>286</volume><issue>2</issue><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">11500056</pub-id></citation></ref><ref id="R35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name></person-group><article-title>Functional studies of the MEN1 gene</article-title><source>J Intern Med</source><year>2003</year><volume>253</volume><issue>6</issue><fpage>606</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">12755956</pub-id></citation></ref><ref id="R36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>La</surname><given-names>P</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Schnepp</surname><given-names>RW</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Direct binding of DNA by tumor suppressor menin</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>47</issue><fpage>49045</fpage><lpage>49054</lpage><pub-id pub-id-type="pmid">15331604</pub-id></citation></ref><ref id="R37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Cho</surname><given-names>EJ</given-names></name><name><surname>Liu</surname><given-names>JO</given-names></name><name><surname>Youn</surname><given-names>HD</given-names></name></person-group><article-title>Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>19</issue><fpage>6135</fpage><lpage>6139</lpage><pub-id pub-id-type="pmid">14559791</pub-id></citation></ref><ref id="R38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name><name><surname>Sanyal</surname><given-names>M</given-names></name><name><surname>Aufiero</surname><given-names>DJ</given-names></name><name><surname>Kitabayashi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><issue>13</issue><fpage>5639</fpage><lpage>5649</lpage><pub-id pub-id-type="pmid">15199122</pub-id></citation></ref><ref id="R39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CM</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Copeland</surname><given-names>TD</given-names></name><name><surname>Levine</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus</article-title><source>Mol Cell</source><year>2004</year><volume>13</volume><issue>4</issue><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">14992727</pub-id></citation></ref><ref id="R40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Hughes</surname><given-names>CM</given-names></name><name><surname>Lloyd</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><issue>3</issue><fpage>749</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">15640349</pub-id></citation></ref><ref id="R41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Somervaille</surname><given-names>TC</given-names></name><name><surname>Smith</surname><given-names>KS</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>ML</given-names></name></person-group><article-title>The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis</article-title><source>Cell</source><year>2005</year><volume>123</volume><issue>2</issue><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16239140</pub-id></citation></ref><ref id="R42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Odom</surname><given-names>DT</given-names></name><name><surname>Crawford</surname><given-names>GE</given-names></name><name><surname>Perkins</surname><given-names>S</given-names></name><name><surname>Halawi</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis</article-title><source>PLoS Genet</source><year>2006</year><volume>2</volume><issue>4</issue><fpage>e51</fpage><pub-id pub-id-type="pmid">16604156</pub-id></citation></ref><ref id="R43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Impey</surname><given-names>S</given-names></name><name><surname>McWeeney</surname><given-names>S</given-names></name><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Goodman</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation</article-title><source>Neoplasia</source><year>2007</year><volume>9</volume><issue>2</issue><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">17356705</pub-id></citation></ref><ref id="R44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itakura</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Katai</surname><given-names>M</given-names></name><name><surname>Ikeo</surname><given-names>Y</given-names></name><name><surname>Hashizume</surname><given-names>K</given-names></name></person-group><article-title>Enhanced sensitivity to alkylating agent in lymphocytes from patients with multiple endocrine neoplasia type 1</article-title><source>Biomed Pharmacother</source><year>2000</year><volume>54</volume><issue>1</issue><fpage>187s</fpage><lpage>190s</lpage><pub-id pub-id-type="pmid">10915021</pub-id></citation></ref><ref id="R45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Schnepp</surname><given-names>RW</given-names></name><name><surname>Sykes</surname><given-names>SM</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name></person-group><article-title>Menin associates with FANCD2, a protein involved in repair of DNA damage</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>14</issue><fpage>4204</fpage><lpage>4210</lpage><pub-id pub-id-type="pmid">12874027</pub-id></citation></ref><ref id="R46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhodolets</surname><given-names>KE</given-names></name><name><surname>Hickman</surname><given-names>AB</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Sukhodolets</surname><given-names>MV</given-names></name><name><surname>Obungu</surname><given-names>VH</given-names></name><name><surname>Novotny</surname><given-names>EA</given-names></name><etal/></person-group><article-title>The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><issue>2</issue><fpage>493</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">12509449</pub-id></citation></ref><ref id="R47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binz</surname><given-names>SK</given-names></name><name><surname>Sheehan</surname><given-names>AM</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><article-title>Replication protein A phosphorylation and the cellular response to DNA damage</article-title><source>DNA Repair (Amst)</source><year>2004</year><volume>3</volume><issue>8-9</issue><fpage>1015</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">15279788</pub-id></citation></ref><ref id="R48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busygina</surname><given-names>V</given-names></name><name><surname>Suphapeetiporn</surname><given-names>K</given-names></name><name><surname>Marek</surname><given-names>LR</given-names></name><name><surname>Stowers</surname><given-names>RS</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name></person-group><article-title>Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13</volume><issue>20</issue><fpage>2399</fpage><lpage>2408</lpage><pub-id pub-id-type="pmid">15333582</pub-id></citation></ref><ref id="R49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busygina</surname><given-names>V</given-names></name><name><surname>Kottemann</surname><given-names>MC</given-names></name><name><surname>Scott</surname><given-names>KL</given-names></name><name><surname>Plon</surname><given-names>SE</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name></person-group><article-title>Multiple Endocrine Neoplasia Type 1 Interacts with Forkhead Transcription Factor CHES1 in DNA Damage Response</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>17</issue><fpage>8397</fpage><lpage>8403</lpage><pub-id pub-id-type="pmid">16951149</pub-id></citation></ref><ref id="R50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Burns</surname><given-names>AL</given-names></name><name><surname>Goldsmith</surname><given-names>PK</given-names></name><name><surname>Heppner</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Stable overexpression of MEN1 suppresses tumorigenicity of RAS</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><issue>43</issue><fpage>5936</fpage><lpage>5942</lpage><pub-id pub-id-type="pmid">10557080</pub-id></citation></ref><ref id="R51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertolino</surname><given-names>P</given-names></name><name><surname>Radovanovic</surname><given-names>I</given-names></name><name><surname>Casse</surname><given-names>H</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Zhang</surname><given-names>CX</given-names></name></person-group><article-title>Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs</article-title><source>Mech Dev</source><year>2003</year><volume>120</volume><issue>5</issue><fpage>549</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12782272</pub-id></citation></ref><ref id="R52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schnepp</surname><given-names>RW</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Masai</surname><given-names>H</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name></person-group><article-title>Functional interaction between tumor suppressor menin and activator of S-phase kinase</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>18</issue><fpage>6791</fpage><lpage>6796</lpage><pub-id pub-id-type="pmid">15374998</pub-id></citation></ref><ref id="R53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biondi</surname><given-names>CA</given-names></name><name><surname>Gartside</surname><given-names>MG</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Loffler</surname><given-names>KA</given-names></name><name><surname>Stark</surname><given-names>MS</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><issue>8</issue><fpage>3125</fpage><lpage>3131</lpage><pub-id pub-id-type="pmid">15060136</pub-id></citation></ref><ref id="R54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Garrett-Beal</surname><given-names>L</given-names></name><name><surname>Emmert-Buck</surname><given-names>MR</given-names></name><name><surname>Edgemon</surname><given-names>KA</given-names></name><etal/></person-group><article-title>A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>3</issue><fpage>1118</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">11158604</pub-id></citation></ref><ref id="R55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>McNally</surname><given-names>SR</given-names></name><name><surname>Swain</surname><given-names>GP</given-names></name><name><surname>Montagna</surname><given-names>C</given-names></name><etal/></person-group><article-title>Of mice and MEN1: Insulinomas in a conditional mouse knockout</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><issue>17</issue><fpage>6075</fpage><lpage>6085</lpage><pub-id pub-id-type="pmid">12917331</pub-id></citation></ref><ref id="R56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suphapeetiporn</surname><given-names>K</given-names></name><name><surname>Greally</surname><given-names>JM</given-names></name><name><surname>Walpita</surname><given-names>D</given-names></name><name><surname>Ashley</surname><given-names>T</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name></person-group><article-title>MEN1 tumor-suppressor protein localizes to telomeres during meiosis</article-title><source>Genes Chromosomes Cancer</source><year>2002</year><volume>35</volume><issue>1</issue><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">12203793</pub-id></citation></ref><ref id="R57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><article-title>Multiple tumor suppressor pathways negatively regulate telomerase</article-title><source>Cell</source><year>2003</year><volume>113</volume><issue>7</issue><fpage>881</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">12837246</pub-id></citation></ref><ref id="R58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Egido</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Oberg</surname><given-names>K</given-names></name><name><surname>Bongcam-Rudloff</surname><given-names>E</given-names></name><name><surname>Gobl</surname><given-names>A</given-names></name></person-group><article-title>Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity</article-title><source>Exp Cell Res</source><year>2002</year><volume>278</volume><issue>2</issue><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">12169273</pub-id></citation></ref><ref id="R59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obungu</surname><given-names>VH</given-names></name><name><surname>Lee Burns</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Chandrasekharapa</surname><given-names>SC</given-names></name><name><surname>Adelstein</surname><given-names>RS</given-names></name><name><surname>Marx</surname><given-names>SJ</given-names></name></person-group><article-title>Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><issue>41</issue><fpage>6347</fpage><lpage>6358</lpage><pub-id pub-id-type="pmid">14508515</pub-id></citation></ref><ref id="R60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heasley</surname><given-names>LE</given-names></name><name><surname>Han</surname><given-names>SY</given-names></name></person-group><article-title>JNK regulation of oncogenesis</article-title><source>Mol Cells</source><year>2006</year><volume>21</volume><issue>2</issue><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">16682809</pub-id></citation></ref><ref id="R61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zebisch</surname><given-names>A</given-names></name><name><surname>Czernilofsky</surname><given-names>AP</given-names></name><name><surname>Keri</surname><given-names>G</given-names></name><name><surname>Smigelskaite</surname><given-names>J</given-names></name><name><surname>Sill</surname><given-names>H</given-names></name><name><surname>Troppmair</surname><given-names>J</given-names></name></person-group><article-title>Signaling through RAS-RAF-MEK-ERK: from basics to bedside</article-title><source>Curr Med Chem</source><year>2007</year><volume>14</volume><issue>5</issue><fpage>601</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">17346150</pub-id></citation></ref><ref id="R62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name></person-group><article-title>Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling</article-title><source>J Gastroenterol</source><year>2006</year><volume>41</volume><issue>4</issue><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">16741607</pub-id></citation></ref><ref id="R63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Greten</surname><given-names>FR</given-names></name></person-group><article-title>NF-kappaB: linking inflammation and immunity to cancer development and progression</article-title><source>Nat Rev Immunol</source><year>2005</year><volume>5</volume><issue>10</issue><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">16175180</pub-id></citation></ref><ref id="R64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>XH</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><article-title>p18Ink4c Collaborates with Men1 to Constrain Lung Stem Cell Expansion and Suppress Non-Small-Cell Lung Cancers</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>7</issue><fpage>3162</fpage><lpage>3170</lpage><pub-id pub-id-type="pmid">17409423</pub-id></citation></ref><ref id="R65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Pei</surname><given-names>XH</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><article-title>p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors</article-title><source>Mol Cell Biol</source><year>2007</year><volume>27</volume><issue>4</issue><fpage>1495</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">17145768</pub-id></citation></ref><ref id="R66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>AJ</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>Chromatin modifications in DNA repair</article-title><source>Results Probl Cell Differ</source><year>2006</year><volume>41</volume><fpage>109</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">16909893</pub-id></citation></ref><ref id="R67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name></person-group><article-title>Mechanism of homologous recombination: mediators and helicases take on regulatory functions</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><issue>10</issue><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">16926856</pub-id></citation></ref><ref id="R68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staalesen</surname><given-names>V</given-names></name><name><surname>Falck</surname><given-names>J</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Bartkova</surname><given-names>J</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alternative splicing and mutation status of CHEK2 in stage III breast cancer</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><issue>52</issue><fpage>8535</fpage><lpage>8544</lpage><pub-id pub-id-type="pmid">15361853</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list id="DL1"><def-item><term>MEN1</term><def><p>Multiple endocrine neoplasia type 1</p></def></def-item><def-item><term>RB1</term><def><p>Retinoblastoma</p></def></def-item><def-item><term>LOH</term><def><p>Loss of heterozygosity</p></def></def-item><def-item><term>DEB</term><def><p>Diepoxybutane</p></def></def-item><def-item><term>MEFs</term><def><p>Mouse embryonic fibroblasts</p></def></def-item><def-item><term>RPA</term><def><p>Replication protein A</p></def></def-item><def-item><term>ES</term><def><p>Embryonic stem</p></def></def-item></def-list></glossary></back><floats-wrap><table-wrap id="T1" position="float"><label>Table 1</label><caption><title>Familial cancer syndromes and cancer predisposition genes [<xref ref-type="bibr" rid="R8">8</xref>-<xref ref-type="bibr" rid="R9">9</xref>]</title></caption><table frame="hsides" rules="groups"><thead align="left"><tr><td rowspan="1" colspan="1">Cancer syndrome</td><td colspan="1" rowspan="1">Type of tumors</td><td colspan="1" rowspan="1">Gene(s)</td><td colspan="1" rowspan="1">Function</td></tr><tr><td rowspan="1" colspan="1">Dominant mode of inheritance</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Familial retinoblastoma</td><td rowspan="1" colspan="1">Retinoblastoma, Osteosarcoma</td><td rowspan="1" colspan="1">RB</td><td rowspan="1" colspan="1">Regulator of cell proliferation</td></tr><tr><td rowspan="1" colspan="1">Li-Fraumeni syndrome</td><td rowspan="1" colspan="1">Soft tissue Osteosarcoma, breast cancer, leukemia</td><td rowspan="1" colspan="1">p53, CHK2 [<xref ref-type="bibr" rid="R68">68</xref>]</td><td rowspan="1" colspan="1">Transcription factor, DNA damage response; Kinase, regulator of p53 activity</td></tr><tr><td rowspan="1" colspan="1">Gorlin syndrome</td><td rowspan="1" colspan="1">Basal cell carcinoma</td><td rowspan="1" colspan="1">PTCH</td><td rowspan="1" colspan="1">Transmembrane receptor for hedgehog</td></tr><tr><td rowspan="1" colspan="1">Familial adenomatous polyposis (FAP)</td><td rowspan="1" colspan="1">Colorectal cancer</td><td rowspan="1" colspan="1">APC</td><td rowspan="1" colspan="1">Regulation of &#x003b2;-catenin</td></tr><tr><td rowspan="1" colspan="1">Hereditary non-polyposis colorectal cancer (HNPCC)</td><td rowspan="1" colspan="1">Colorectal cancer</td><td rowspan="1" colspan="1">MSH2, 6, MLH1, PMS1, 2</td><td rowspan="1" colspan="1">Mismatch repair</td></tr><tr><td rowspan="1" colspan="1">Neurofibromatosis type 1</td><td rowspan="1" colspan="1">Neurofibromas</td><td rowspan="1" colspan="1">NF1</td><td rowspan="1" colspan="1">GAP for p21</td></tr><tr><td rowspan="1" colspan="1">Neurofibromatosis type 2</td><td rowspan="1" colspan="1">Schwannomas, Meningiomas</td><td rowspan="1" colspan="1">NF2</td><td rowspan="1" colspan="1">Links membrane proteins to cytoskeleton</td></tr><tr><td rowspan="1" colspan="1">Familial breast/ovarian cancer syndrome</td><td rowspan="1" colspan="1">Breast cancer, ovarian cancer</td><td rowspan="1" colspan="1">BRCA1/2</td><td rowspan="1" colspan="1">DNA repair</td></tr><tr><td rowspan="1" colspan="1">von Hippel-Lindau syndrome</td><td rowspan="1" colspan="1">Renal cancer (clear cell)</td><td rowspan="1" colspan="1">VHL</td><td rowspan="1" colspan="1">Transcription elongation factor</td></tr><tr><td rowspan="1" colspan="1">Hereditary papillary renal cancer (HPRC)</td><td rowspan="1" colspan="1">Renal cancer (papillary)</td><td rowspan="1" colspan="1">MET</td><td rowspan="1" colspan="1">Transmembrane receptor for HGF</td></tr><tr><td rowspan="1" colspan="1">Familial melanoma</td><td rowspan="1" colspan="1">Melanoma</td><td rowspan="1" colspan="1">p16</td><td rowspan="1" colspan="1">Cyclin-dependent kinases CDK4 and CDK 6 inhibitor</td></tr><tr><td rowspan="1" colspan="1">Multiple endocrine neoplasia type 1 (MEN1)</td><td rowspan="1" colspan="1">Pituitary Parathyroid adenoma, Pancreatic islet</td><td rowspan="1" colspan="1">MEN1</td><td rowspan="1" colspan="1">Transcriptional regulator, modulator of AP-1 activity</td></tr><tr><td rowspan="1" colspan="1">Multiple endocrine neoplasia type 2 (MEN2)</td><td rowspan="1" colspan="1">Medullary thyroid cancer</td><td rowspan="1" colspan="1">RET</td><td rowspan="1" colspan="1">Transmembrane receptor</td></tr><tr><td rowspan="1" colspan="1">Cowden disease</td><td rowspan="1" colspan="1">Breast cancer, thyroid cancer</td><td rowspan="1" colspan="1">PTEN</td><td rowspan="1" colspan="1">PI3kinase/AKT inhibitor, phosphatase</td></tr><tr><td rowspan="1" colspan="1">Tuberous sclerosis</td><td rowspan="1" colspan="1">Rabdomyoma, Renal cancer</td><td rowspan="1" colspan="1">TSCI/2</td><td rowspan="1" colspan="1">Regulation of cell size and proliferation through insulin signaling</td></tr><tr><td colspan="1" align="center" rowspan="1">Recessive mode of inheritance</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Bloom syndrome</td><td rowspan="1" colspan="1">Solid tumors</td><td rowspan="1" colspan="1">BLM</td><td rowspan="1" colspan="1">Helicase, DNA repair</td></tr><tr><td rowspan="1" colspan="1">Ataxia telangiectasia (AT)</td><td rowspan="1" colspan="1">Lymphoma</td><td rowspan="1" colspan="1">ATM</td><td rowspan="1" colspan="1">DNA repair, DNA damage response</td></tr><tr><td rowspan="1" colspan="1">Nijmegen breakage syndrome (NBS)</td><td rowspan="1" colspan="1">Lymphoma, Glioma, Medulloblastoma</td><td rowspan="1" colspan="1">NBS1</td><td rowspan="1" colspan="1">Double strand break repair</td></tr><tr><td rowspan="1" colspan="1">Xeroderma pigmentosum</td><td rowspan="1" colspan="1">Skin cancer</td><td rowspan="1" colspan="1">XPB, XPD, XPA</td><td rowspan="1" colspan="1">Nucleotide excision repair</td></tr><tr><td rowspan="1" colspan="1">Rothmund Thompson syndrome</td><td rowspan="1" colspan="1">Basal cell carcinoma, Squamous cell sarcoma</td><td rowspan="1" colspan="1">RECQL4</td><td rowspan="1" colspan="1">Helicase</td></tr><tr><td rowspan="1" colspan="1">Werner syndrome</td><td rowspan="1" colspan="1">Oseeosarcoma, Meningioma</td><td rowspan="1" colspan="1">WRN</td><td rowspan="1" colspan="1">Helicase</td></tr><tr><td rowspan="1" colspan="1">Fanconi anemia</td><td rowspan="1" colspan="1">Leukemia, Squamous cancers</td><td rowspan="1" colspan="1">FANCD2, FANCA, FANCB, C, FANCE, F, FANCG, L</td><td rowspan="1" colspan="1">DNA repair, DNA damage response</td></tr></tbody></table><table-wrap-foot><fn id="TF1-150"><p>Abbreviations: GAP - GTPase-activating protein; MSN - mut S homolog; MLH - mut L homolog; PMS - postmeiotic segregation; HGF - hepatocyte growth factor; BRCA - breast cancer associated; PTEN - phosphatase and tensin homolog.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 